We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers incl... Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company¿s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. Show more
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.24 | 15.1898734177 | 1.58 | 1.87 | 1.5311 | 4778842 | 1.66941827 | CS |
4 | 0.37 | 25.5172413793 | 1.45 | 1.87 | 1.29 | 6393948 | 1.52628659 | CS |
12 | 0.95 | 109.195402299 | 0.87 | 1.87 | 0.7178 | 4165492 | 1.3427716 | CS |
26 | 1.5463 | 564.961636829 | 0.2737 | 1.87 | 0.2201 | 2753609 | 1.12672707 | CS |
52 | 1.2001 | 193.595741249 | 0.6199 | 1.87 | 0.205 | 1691171 | 0.98031747 | CS |
156 | 1.4437 | 383.656656923 | 0.3763 | 1.87 | 0.205 | 1522131 | 0.9506168 | CS |
260 | 1.4437 | 383.656656923 | 0.3763 | 1.87 | 0.205 | 1522131 | 0.9506168 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions